Clinical Trial Update: Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is investigating sacituzumab tirumotecan with limertinib for potentially resectable stage III EGFR-mutant non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Limertinib (Limertinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable | Phase 2 | Status: RECRUITING